TNF Pharmaceuticals Files 8-K on Material Agreement
Ticker: QCLS · Form: 8-K · Filed: Aug 14, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Aug 14, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action, filing
TL;DR
TNF Pharma (TNF) filed an 8-K on 8/8/24 for a material agreement & changes to shareholder rights.
AI Summary
On August 8, 2024, TNF Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The company, formerly known as MyMD Pharmaceuticals, Inc., also reported modifications to security holder rights and amendments to its articles of incorporation or bylaws. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions and potential changes in the rights of security holders for TNF Pharmaceuticals, Inc., which could impact investors.
Risk Assessment
Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce significant changes and potential risks for investors.
Key Numbers
- 001-36268 — SEC File Number (Identifies the company's filing history with the SEC.)
- 22-2983783 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Registrant
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- August 8, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the nature of the material definitive agreement filed by TNF Pharmaceuticals?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What specific modifications were made to the rights of security holders?
The filing states there were material modifications to the rights of security holders, but the exact nature of these modifications is not detailed in the excerpt.
What are the key items reported in this 8-K filing?
The key items reported are entry into a material definitive agreement, material modifications to rights of security holders, amendments to articles of incorporation or bylaws, and financial statements and exhibits.
When was the company formerly known as MyMD Pharmaceuticals, Inc.?
The company's name changed from MyMD Pharmaceuticals, Inc. on April 20, 2021.
What is the business address of TNF Pharmaceuticals, Inc.?
The business address is 855 N. WOLFE STREET, SUITE 601, BALTIMORE, MD 21205.
Filing Stats: 792 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-08-14 16:05:54
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TNFA The Nasdaq Capital M
- $1,000 — Preferred Stock, with a stated value of $1,000 per share (the "Preferred Stock"), and
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex3-1.htm (EX-3.1) — 14KB
- ex10-1.htm (EX-10.1) — 27KB
- 0001493152-24-032169.txt ( ) — 264KB
- tnfa-20240808.xsd (EX-101.SCH) — 3KB
- tnfa-20240808_lab.xml (EX-101.LAB) — 33KB
- tnfa-20240808_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TNF PHARMACEUTICALS, INC. Date: August 14, 2024 By: /s/ Joshua Silverman Name: Joshua Silverman Title: Director